Boston Scientific initiated with an Outperform, $59 price target at Baird

As previously reported, Baird initiated coverage of Boston Scientific with an Outperform rating and $59 price target. The global MedTech player has a durable trajectory of “best-in-class” high-single digit top-line and double-digit adjusted EPS growth among large-cap diversified MedTech peers, the analyst tells investors. Boston Scientific’s “market leading” portfolio is poised to benefit from an ongoing recovery of procedures and a broader shift toward the outpatient setting, the analyst added.